The future of drug development: advancing clinical trial design

Declining pharmaceutical industry productivity is well recognized by drug developers, regulatory authorities and patient groups. A key part of the problem is that clinical studies are increasingly expensive, driven by the rising costs of conducting Phase II and III trials. It is therefore crucial to ensure that these phases of drug development are conducted more efficiently and cost-effectively, and that attrition rates are reduced. In this article, we argue that moving from the traditional clinical development approach based on sequential, distinct phases towards a more integrated view that uses adaptive design tools to increase flexibility and maximize the use of accumulated knowledge could have an important role in achieving these goals. Applications and examples of the use of these tools — such as Bayesian methodologies — in early- and late-stage drug development are discussed, as well as the advantages, challenges and barriers to their more widespread implementation.

[1]  Victor C. Strasburger,et al.  Review and Recommendations , 1983 .

[2]  M Danhof,et al.  Relevance of the Application of Pharmacokinetic-Pharmacodynamic Modelling Concepts in Drug Development , 1997, Clinical pharmacokinetics.

[3]  Carl Peck,et al.  An Evaluation of the Integration of Pharmacokinetic and Pharmacodynamic Principles in Clinical Drug Development , 1997, Clinical pharmacokinetics.

[4]  L B Sheiner,et al.  Pharmacokinetic/pharmacodynamic modeling in drug development. , 2000, Annual review of pharmacology and toxicology.

[5]  N H Holford,et al.  Simulation of clinical trials. , 2000, Annual review of pharmacology and toxicology.

[6]  A. Stevens Industrial perspective. , 2000, Ultrasound in medicine & biology.

[7]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[8]  R. Frank,et al.  New estimates of drug development costs. , 2003, Journal of health economics.

[9]  A. Tsiatis,et al.  On the inefficiency of the adaptive design for monitoring clinical trials , 2003 .

[10]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[11]  M. Danhof,et al.  Mechanism-Based Pharmacokinetic–Pharmacodynamic Modeling—A New Classification of Biomarkers , 2005, Pharmaceutical Research.

[12]  B. Corrigan,et al.  How Modeling and Simulation Have Enhanced Decision Making in New Drug Development , 2005, Journal of Pharmacokinetics and Pharmacodynamics.

[13]  Donald A Berry,et al.  Introduction to Bayesian methods III: use and interpretation of Bayesian tools in design and analysis , 2005, Clinical trials.

[14]  Van V. Brantner,et al.  Estimating the cost of new drug development: is it really 802 million dollars? , 2006, Health affairs.

[15]  Frank Bretz,et al.  Confirmatory Seamless Phase II/III Clinical Trials with Hypotheses Selection at Interim: General Concepts , 2006, Biometrical journal. Biometrische Zeitschrift.

[16]  Paul Gallo,et al.  Sample Size Reestimation: A Review and Recommendations , 2006 .

[17]  Howard L Golub The need for more efficient trial designs. , 2006, Statistics in medicine.

[18]  Cyrus R Mehta,et al.  Adaptive, group sequential and decision theoretic approaches to sample size determination , 2006, Statistics in medicine.

[19]  D. Berry Bayesian clinical trials , 2006, Nature Reviews Drug Discovery.

[20]  M. Krams,et al.  Adaptive Designs in Clinical Drug Development—An Executive Summary of the PhRMA Working Group , 2006, Journal of biopharmaceutical statistics.

[21]  Min Huang,et al.  Large-Sample Bayesian Posterior Distributions for Probabilistic Sensitivity Analysis , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.

[22]  M. Krams,et al.  Adaptive Designs in Clinical Drug Development: Opportunities, Challenges, and Scope Reflections Following PhRMA's November 2006 Workshop , 2007, Journal of biopharmaceutical statistics.

[23]  Donald A. Berry,et al.  Simulation-based sequential Bayesian design , 2007 .

[24]  M. Krams,et al.  Innovative Approaches for Designing and Analyzing Adaptive Dose-Ranging Trials , 2007, Journal of biopharmaceutical statistics.

[25]  D. Berry Adaptive trial design. , 2007, Clinical advances in hematology & oncology : H&O.

[26]  Christopher J Weir,et al.  Flexible Design and Efficient Implementation of Adaptive Dose-Finding Studies , 2007, Journal of biopharmaceutical statistics.

[27]  W Ewy,et al.  Model‐based Drug Development , 2007, Clinical pharmacology and therapeutics.

[28]  J. Mccrate,et al.  The effects of linking substituents on the in vivo behavior of site-directed, peptide-based, diagnostic radiopharmaceuticals. , 2007, In vivo.

[29]  Christopher Adams,et al.  Spending on New Drug Development , 2008 .

[30]  P. Hawkins,et al.  Use of canakinumab in the cryopyrin-associated periodic syndrome. , 2009, The New England journal of medicine.

[31]  José M. Bernardo,et al.  Bayesian Statistics , 2011, International Encyclopedia of Statistical Science.

[32]  James L. Gilbert,et al.  Rebuilding Big Pharma ’ s Business Model , 2022 .